Kiniksa Pharmaceuticals Ltd (KNSA) support and resistance · P/E 53, rev $677.6M
Kiniksa Pharmaceuticals Ltd (KNSA) is a drug manufacturers - specialty & generic company listed on US.
This page maps Kiniksa Pharmaceuticals Ltd (KNSA) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported KNSA revenue for 2025-12-31 was $677.6M. Net income was $59.0M. Revenue was up 60.1% from 2024-12-31 to 2025-12-31. KNSA currently screens at market cap $3.73B and trailing P/E 53.2.
KNSA currently screens at market cap $3.73B and trailing P/E 53.2. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new KNSA 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the KNSA quote page for the session range and the stock page for the full model.
Not investment advice.